liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer - A national survey performed at pathology departments in Sweden
Lund University Hospital.
Malmö University Hospital.
Lund University Hospital.
Karolinska University Hospital.
Show others and affiliations
2009 (English)In: ACTA ONCOLOGICA, ISSN 0284-186X, Vol. 48, no 6, 860-866 p.Article in journal (Refereed) Published
Abstract [en]

Background. HER2 is a treatment predictive factor for the effect of trastuzumab and associated with poor prognosis in breast cancer. The analysis of HER2 must be performed with good quality, with regard to both the immunohistochemical (IHC) and in situ hybridization (ISH) analysis. Material and methods. A tissue microarray (TMA) including 11 breast cancer samples was sent twice (once in 2005 and again in 2006) to 24 pathology departments in Sweden. A questionnaire was also sent to the departments in 2006. Results. With IHC, all departments reported the same results (0/1+ vs. 2+ vs. 3+) for three (2005) and six samples (2006). The mean kappa-value increased from 0.67 to 0.77, indicating a good reproducibility at both occasions. With fluorescence-ISH (FISH), the 11 departments using this technique reported the same results (amplified vs. normal) for nine (2005) and ten samples (2006). The mean kappa-value showed very good reproducibility both 2005 and 2006 (0.92 and 0.96, respectively). Based on the answers from the participating departments, the questionnaire revealed that 31% of primary breast cancer diagnosed in 2006 (n = 5 043) were 2+/3+. FISH analysis of 2+ confirmed 12% of the samples to be amplified. The corresponding figure for 3+ was 90%. In total, 14.3% of the samples were HER2 positive (2+ and amplified, or 3+). Discussion. The results obtained in this study indicate that the reproducibility for HER2 analysis is good (IHC) and very good (FISH) between the pathology departments in Sweden using TMA-based tumor samples. In 2006, 14.3% of invasive breast cancers were HER2 positive.

Place, publisher, year, edition, pages
2009. Vol. 48, no 6, 860-866 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-20418DOI: 10.1080/02841860902862511OAI: diva2:234528
Available from: 2009-09-08 Created: 2009-09-07 Last updated: 2009-09-08

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Olsson, Hans
By organisation
Molecular and Immunological Pathology Faculty of Health SciencesDepartment of Clinical Pathology and Clinical Genetics
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 24 hits
ReferencesLink to record
Permanent link

Direct link